Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 80

1.

The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists.

Rasmussen VG, Østergaard K, Dupont E, Poulsen SH.

Mov Disord. 2011 Apr;26(5):801-6. Review.

PMID:
21671508
[PubMed - indexed for MEDLINE]
2.

Valvular heart disease and the use of dopamine agonists for Parkinson's disease.

Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G.

N Engl J Med. 2007 Jan 4;356(1):39-46.

PMID:
17202454
[PubMed - indexed for MEDLINE]
Free Article
3.

High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.

Oeda T, Masaki M, Yamamoto K, Mizuta E, Kitagawa N, Isono T, Taniguchi S, Doi K, Yaku H, Yutani C, Kawamura T, Kuno S, Sawada H.

J Neural Transm. 2009 Feb;116(2):171-8. doi: 10.1007/s00702-008-0160-2. Epub 2008 Dec 10.

PMID:
19082526
[PubMed - indexed for MEDLINE]
4.

Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease.

Rasmussen VG, Poulsen SH, Dupont E, Østergaard K, Safikhany G, Egeblad H.

J Intern Med. 2008 Jan;263(1):90-8. Epub 2007 Nov 23.

PMID:
18036161
[PubMed - indexed for MEDLINE]
5.

[Valvular heart disease associated with the treatment of Parkinson disease].

Rasmussen VG, Dupont E, Østergaard K, Egeblad H.

Ugeskr Laeger. 2006 Jun 26;168(26-32):2542-4. Review. Danish.

PMID:
16824407
[PubMed - indexed for MEDLINE]
6.

Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review.

Steiger M, Jost W, Grandas F, Van Camp G.

J Neural Transm. 2009 Feb;116(2):179-91. doi: 10.1007/s00702-008-0179-4. Epub 2009 Jan 14. Review.

PMID:
19142570
[PubMed - indexed for MEDLINE]
7.

Valvular heart disease in patients with Parkinson's disease treated with pergolide. Course following treatment modifications.

Dupuy D, Lesbre JP, Gérard P, Andrejak M, Godefroy O.

J Neurol. 2008 Jul;255(7):1045-8. doi: 10.1007/s00415-008-0839-1. Epub 2008 Jun 16.

PMID:
18560792
[PubMed - indexed for MEDLINE]
8.

Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study.

Trifirò G, Mokhles MM, Dieleman JP, van Soest EM, Verhamme K, Mazzaglia G, Herings R, de Luise C, Ross D, Brusselle G, Colao A, Haverkamp W, Schade R, van Camp G, Zanettini R, Sturkenboom MC.

Drug Saf. 2012 Feb 1;35(2):159-71. doi: 10.2165/11594940-000000000-00000.

PMID:
22204718
[PubMed - indexed for MEDLINE]
9.

Ergoline and non-ergoline derivatives in the treatment of Parkinson's disease.

Reichmann H, Bilsing A, Ehret R, Greulich W, Schulz JB, Schwartz A, Rascol O.

J Neurol. 2006 Aug;253 Suppl 4:IV36-8. Erratum in: J Neurol. 2008 Sep;255(9):1444.

PMID:
16944356
[PubMed - indexed for MEDLINE]
10.

Heart abnormalities in Parkinson patients after discontinuation or continuation of ergot-derived dopamine agonists: a treatment-blinded echocardiographic study.

Rasmussen VG, Poulsen SH, Dupont E, Østergaard K, Safikhany G, Egeblad H.

J Heart Valve Dis. 2009 Jul;18(4):463-9.

PMID:
19852154
[PubMed - indexed for MEDLINE]
11.

Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.

Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D.

Lancet. 2004 Apr 10;363(9416):1179-83.

PMID:
15081648
[PubMed - indexed for MEDLINE]
12.

Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.

Simonis G, Fuhrmann JT, Strasser RH.

Mov Disord. 2007 Oct 15;22(13):1936-42.

PMID:
17659636
[PubMed - indexed for MEDLINE]
13.

Dopamine agonists and the risk of cardiac-valve regurgitation.

Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E.

N Engl J Med. 2007 Jan 4;356(1):29-38.

PMID:
17202453
[PubMed - indexed for MEDLINE]
Free Article
14.

Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.

Kim JY, Chung EJ, Park SW, Lee WY.

Mov Disord. 2006 Aug;21(8):1261-4.

PMID:
16685692
[PubMed - indexed for MEDLINE]
15.

Heart valve abnormalities in Parkinson's disease treated with dopamine agonists.

Bares M, Rektorová I, Krajcovicová L, Rektor I.

J Neurol. 2008 Oct;255(10):1596; author reply 1597. doi: 10.1007/s00415-008-0972-x. Epub 2008 Sep 3. No abstract available.

PMID:
18758889
[PubMed - indexed for MEDLINE]
16.

Dopamine agonists and valvular heart disease.

Cheung D, Heaney A.

Curr Opin Endocrinol Diabetes Obes. 2009 Aug;16(4):316-20. doi: 10.1097/MED.0b013e32832d9f64. Review.

PMID:
19506475
[PubMed - indexed for MEDLINE]
17.

Bromocriptine use and the risk of valvular heart disease.

Tan LC, Ng KK, Au WL, Lee RK, Chan YH, Tan NC.

Mov Disord. 2009 Feb 15;24(3):344-9. doi: 10.1002/mds.22228.

PMID:
18989898
[PubMed - indexed for MEDLINE]
18.

Dopamine agonists and valvular heart disease.

Linkova H, Ruzicka E, Penicka M.

N Engl J Med. 2007 Apr 19;356(16):1676; author reply 1678-80. No abstract available.

PMID:
17447279
[PubMed - indexed for MEDLINE]
19.

Pergolide in Parkinson's disease: time for a change?

Grosset KA, Grosset DG.

Lancet. 2004 Jun 5;363(9424):1907-8. No abstract available.

PMID:
15183636
[PubMed - indexed for MEDLINE]
20.

Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide.

Růzicka E, Línková H, Penicka M, Ulmanová O, Nováková L, Roth J.

J Neurol. 2007 Nov;254(11):1575-8. Epub 2007 Aug 24.

PMID:
17712588
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk